The US Food and Drug Administration (FDA) is increasing its pace of approvals for novel cancer therapeutics, including for immune checkpoint inhibitors of programmed cell death 1 protein (anti-PD-1 agents). However, little is known about how quickly anti-PD-1 agents reach eligible patients in practice or whether such patients differ from those studied in clinical trials that lead to FDA approval (pivotal clinical trials).
M ajor advancements have taken place in cancer research and drug development during the past 5 years, with the US Food and Drug Administration (FDA) designating more than 45 anticancer agents as breakthrough therapies. 1 Increasing enthusiasm exists for further accelerations in the pace of drug development, as evidenced by the Cancer Moonshot and the 21st Century Cures Act. 2, 3 However, such initiatives often aim to accelerate the pace of FDA approval-a process that is already rather brisk for new drugs 4 -rather than the pace at which novel therapeutics are adopted among patients who need treatment. In fact, whereas conventional wisdom suggests it most often takes more than 10 years for innovations to change patient care, [5] [6] [7] [8] little is known about how quickly novel therapeutics are reaching patients with cancer in clinical practice. One concern about the adoption of novel therapeutics for cancer is that they may be entering the market before data are available to support their use in the general population. 9, 10 There is particular concern regarding the adequacy of trial data underlying recent approvals of anticancer agents that often enter the market based on preliminary assessments of risks and benefits. 11, 12 Rapid adoption of these agents may harm patients if little is known about the effects of treatment on clinical outcomes. 13 Slow adoption, however, may harm patients similarly by limiting their access to anticancer agents that are innovative and perhaps efficacious. In this context, immune checkpoint inhibitors of programmed cell death 1 protein (anti-PD-1 agents) provide an ideal opportunity to study the adoption of novel therapeutics after FDA approval. Anti-PD-1 agents boost T-cell-mediated antitumor activity, which in turn can lead to major clinical responses. [14] [15] [16] [17] [18] [19] [20] Increasing evidence exists to support their use in multiple cancer types, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). 21, 22 However, the first FDA approvals for these agents cited preliminary evidence of efficacy, with some approvals granted based on single-arm studies that were neither randomized nor controlled.
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The use of anti-PD-1 agents is further complicated-like any new class of agents that first enter to market-by concerns that patients treated in practice might differ in age from patients treated in clinical trials that lead to FDA approvals (pivotal clinical trials). [25] [26] [27] [28] [29] This issue is particularly relevant to checkpoint inhibitors because of age-related changes in immunity that might alter risks and benefits. 30 Although most studies [30] [31] [32] have suggested that checkpoint inhibitors are effective regardless of age, others 33,34 have questioned their efficacy in older adults because the relatively small numbers of older participants in trials preclude a clear understanding of whether age moderates the effects of anti-PD-1 treatment. In an era of increasing enthusiasm for checkpoint inhibitors 35 but also of concern regarding the generalizability of trial evidence with regard to patient age, it is uncertain whether questions about the ages of trial participants might be influencing the adoption of these paradigm-shifting drugs.
To address these knowledge gaps, we studied the adoption of anti-PD-1 agents among patients in real-world practice. Because of uncertainty regarding the use of these agents to treat older patients, 33 we completed 2 additional analyses. First, we assessed the use of each agent across age distributions of patients treated in real-world practice. Second, we compared the age distributions of patients treated in practice with those of patients treated in pivotal clinical trials to assess whether clinical trials matched with the later clinical use of each drug.
Methods

Study Design
We conducted a retrospective cohort study of patients receiving systemic anticancer treatment from January 1, 2011, through August 31, 2016. To ensure adequate follow-up time, we included only patients eligible for treatment with nivolumab or pembrolizumab for previously treated or untreated melanoma, with nivolumab or pembrolizumab for previously treated NSCLC, or with nivolumab for previously treated RCC. We did not assess the rate of adoption of the drug atezolizumab, an inhibitor of programmed cell death 1 ligand 1 (PD-L1), because of limited follow-up time after its approval for urothelial carcinoma on May 18, 2016. The New England Independent Review Board approved the study and waived informed consent because all data were deidentified and collected as part of routine clinical practice.
Data Source
We used electronic health record (EHR) data from the Flatiron Health longitudinal EHR database, which included 233 academic and community oncology practices. 36 Although these practices were self-selected, their use of a cloud-based EHR platform allowed for the integration of real-world evidence from a large, geographically diverse cohort of patients with melanoma, NSCLC, or RCC. Furthermore, these patients were similar in age, sex, and race/ethnicity to the US population of patients with melanoma, NSCLC, and RCC according to estimates of disease prevalence in Surveillance, Epidemiology, and End Results data from 2014. 37 To create our data sets, we com-oncogene homologue B1 (BRAF) (OMIM 164757) mutation status, and PD-L1 expressivity.
Cohort Selection
We applied prespecified inclusion and exclusion criteria to construct cohorts (eFigures 1-3 in the Supplement). We included patients 18 years or older who underwent treatment for (1) 
Identification of Pivotal Clinical Trials
For each cancer type, we used FDA reviews and labels to identify pivotal clinical trials, which are the primary sources of evidence for efficacy underlying FDA approvals. 11 We selected clinical trials that were identified in FDA reviews or labels as the only sources of data regarding efficacy or as the primary sources of data regarding efficacy. For each clinical trial, 2 investigators (J.O. and K.F.) used FDA reviews and labels to separately abstract the sample sizes and age distributions of treatment groups, with differences resolved by consensus. If sample sizes or age distributions were missing from FDA reviews or labels, they were abstracted from publications in peerreviewed journals. If trial results were not published, they were requested from trial sponsors.
Statistical Analysis
We used descriptive statistics to assess characteristics of patients eligible for anti-PD-1 treatment. Patients became eligible for treatment when starting a new line of systemic anticancer therapy (with or without an anti-PD-1 agent) after the date of FDA approval in any setting for which they met eligibility criteria (eFigure 4 in the Supplement). Among eligible patients, we used a cumulative uptake measure to identify the total number and proportion of patients receiving each agent each month. All patients becoming eligible or receiving anti-PD-1 treatment were retained in the respective numerators or denominators for the remainder of the study to allow for cumulative assessments. Finally, we used χ 2 tests to compare age distributions of patients treated in real-world cohorts with those of patients treated in pivotal clinical trials and to assess for differences in distributions of anti-PD-1 treatment among eligible patients by age, with the level of significance being a 2-sided P < .05. All statistical analyses were performed using R, version 3.3.2 (R Foundation for Statistical Computing).
Results
Baseline Characteristics
Of (Figure 1) . At the end of the study period, the numbers of eligible patients having received anti-PD-1 treatment were 439 patients with melanoma (79.1%), 1417 patients with NSCLC (65.6%), and 267 patients with RCC (71.2%).
There was rapid uptake of pembrolizumab for melanoma in the first 3 months after FDA approval, with 31 of 44 eligible patients (70.4%) receiving anti-PD-1 treatment. During the next 12 months, nivolumab surpassed pembrolizumab as the preferred anti-PD-1 agent for melanoma ( Figure 1 ). We found rapid adoption of nivolumab but not pembrolizumab in the treatment of NSCLC, with 72 of 2008 eligible patients (3.6%) receiving pembrolizumab. Overall, 27 patients received both anti-PD-1 agents (26 sequentially and 1 concurrently) despite little or no evidence supporting such use.
Pivotal Clinical Trials Supporting FDA Approvals of Anti-PD-1 Agents
We identified characteristics of patients treated in pivotal clinical trials underlying initial FDA approvals of each anti-PD-1 agent across cancer types and subtypes (eTable 2 in the Supplement). Single pivotal trials supported each approval except for nivolumab in squamous NSCLC, which was supported by 2 pivotal trials. Four of the 7 pivotal trials reported objective responses as the primary outcome, and all 7 reported median follow-up times of 1 year or less. Treatment groups ranged in size from 61 Table 2) . However, with up to 9 months of follow-up for each cohort, the proportional uptake of each agent was similar across distributions of patient age ( Table 3 ). This finding suggests that patient age is unlikely to be associated with consistent differences in the clinical adoption of anti-PD-1 agents (Figure 2 ).
Discussion
We found rapid adoption of anti-PD-1 agents after FDA approvals, including after approvals that were based on limited evidence with regard to the sample sizes and age distributions of trial participants. Such rapid adoption stands in contrast to older estimates that suggest it takes years or even decades for new treatments to be adopted, 5 including evidence that highly effective treatments, such as tamoxifen for breast cancer, can take more than 10 years to reach most eligible patients. 39 Therefore, our findings are both encouragingbecause physicians are rapidly responding to approvals of novel treatments and incorporating them into practice-and concerning-because rapid adoption of treatments might occur without an adequate understanding of risks and benefits. 40 Because our sample included mostly community-based practices, our findings also contradict the notion that early access to treatment is limited to academic centers. Finally, we found significant differences in age between patients treated in practice and those treated in trials, which highlights the need to clarify the risks and benefits of checkpoint inhibitors in general populations of patients. Several factors might have contributed to rapid adoption, including high disease severity, overall preference for novelty, perceived gains over existing treatments, and promotional activities, which include media reports and direct to consumer advertisements. 9, 41 Three of these factors might best explain rapid adoption of anti-PD-1 agents. First, anti-PD-1 agents offered large gains in efficacy to selected patients in part because these agents led to better survival in trials but also because they at times led to major and durable responses to treatment. 42 This property is understandably important to patients with advanced cancers, who often have poor prognoses and few options for treatment. Second, adverse effects of checkpoint inhibitors are different from those of traditional cancer treatments. It is possible that differences in adverse effect profiles might have further reinforced the early use of anti-PD-1 agents. Third, there have been high levels of spending to market these drugs to practitioners and patients. 43 In fact, amid unprecedented levels of spending on direct to consumer advertisements of drugs, both nivolumab and pembrolizumab, which might benefit less than 10% of cancer patients, 44 have ranked among the most advertised drugs of all types. Our finding of rapid adoption is notable in part because of wide variation in the strength of trial evidence underlying recent FDA approvals. 11, 12 We found similar variation underly- 54 and it has been rare for these programs to support approvals of oncology products that are withdrawn because of concerns about safety or efficacy. 55 As FDA officials develop more flexible standards for approval, which the 21st Century Cures Act requires them to do, 3 it is possible that many patients will receive drugs before much is known about clinical outcomes. It will be critical in this context for FDA officials to clarify core principles, to apply such principles consistently, and to include patients in decisions regarding risks that are tolerable in exchange for more rapid access to drugs.
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In this context, further integration of real-world evidence might allow the FDA to better assess the drugs that they approve on the basis of nonrepresentative trial participants. 56, 57 Real-world evidence is important in particular because of findings of substantial differences in age between patients receiving anti-PD-1 agents in practice and those receiving the agents in pivotal trials. 57 Although data suggest that outcomes are similar between older and younger patients receiving anti-PD-1 agents for melanoma, 31 there is little evidence to guide anti-PD-1 treatment of older patients with NSCLC. 34, 58 To improve the evidence that supports the treatment of older patients, the FDA plans to adopt recommendations from the American Society of Clinical Oncology, 59 which include strengthening the FDA's authority to regulate trial enrollment, integrating tools into trials to assess age-specific outcomes, and requiring journals to report outcomes by patient age. 60 One key challenge in oncology is to take advantage of the strengths of EHR platforms to study the effects of novel treatments on clinical end points and patient-reported outcomes. At the same time, there is a need to improve the veracity and utility of EHR data sets, which often are cluttered with inputs to support billing rather than clinical practice. In our study, we have found that novel, integrated sources of real-world evidence can provide important insights about the adoption of drugs. However, given such rapid adoption, it is also critical to leverage real-world evidence to further evaluate how well these drugs work.
Limitations
Our study has several limitations. First, because we studied a sample of mostly community-based practices, our findings might not be generalizable to academic or safety-net practices, and we cannot exclude the possibility that adoption might be faster in practices that use novel EHR platforms. Second, because we assessed anti-PD-1 agents in FDA-approved contexts, future studies are needed to assess their use in contexts without FDA approval (off label) and to assess how differences in coverage or costs might underlie differences in adoption, for example, among anti-PD-1 agents in NSCLC treatment. Third, because we designed a study to assess adoption, about which little is known, we did not assess clinical outcomes, which can be assessed in future work. Fourth, because this analysis is a snapshot of rapidly changing knowledge, practice patterns may change quickly with regard to the use of anti-PD-1 treatment. For example, PD-L1 testing may increase as clinicians become more aware of the use of this test.
Conclusions
In summary, we found rapid adoption of anti-PD-1 treatment among patients in practice. This finding indicates that clinical practice can change promptly and substantially when novel cancer therapeutics first enter the market-in opposition to traditional teaching, which holds that clinicians are slow to respond to new evidence. Although most studies have confirmed the effectiveness of anti-PD-1 treatment in FDAapproved contexts, 61, 62 studies have also found that their safety and efficacy can vary across cancer types and lines of therapy. [63] [64] [65] This variability is a reminder that postapproval studies are imperative when novel treatments enter the market. Furthermore, reasonable enthusiasm for such treatments should be tempered by an expectation that later studies might not support their broad use. 10 Our second major finding-that patients treated in practice were significantly older than patients treated in trials-reflects gaps in knowledge of outcomes among trial participants who represent real-world patients. Future efforts are needed to ensure that the FDA bases its approvals on more generalizable evidence to support the rapid adoption of drugs. 
